Dermatological Drugs Market Forecast 2016-2026

04 September 2016
Pharma

A new report by visiongain predicts that the Dermatological Drugs market will reach $39.25bn in 2026. This forecast and others appear in - Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma published in July 2016. Visiongain is a business information provider based in London, UK.
The Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma, report examines the current and future trends in the Dermatological Drugs Market with particular focus on recent pivotal developments in the sector including patent expiries, biosimilar approvals, patent invalidations, launch of new drugs and pipeline products. These developments in addition to changes in population demographics are changing the landscape of the dermatological drugs market.

Dermatological Drugs are used to treat and manage a wide variety of skin conditions from skin infections, dermatitis, psoriasis and acne. These dermatological diseases are very common, leading to a large patient population.

The driving force behind growth in this market is the high unmet clinical need for dermatological conditions, a healthy pipeline of development-stage products and new products launching onto the market as well as advances in drug delivery options. As the global population ages there is an increased demand for treatment of intermittent or long-standing conditions, in addition to an increased demand from populations in both emerging and developed economies to improve skin care and health. The highly fragmented dermatological drugs market is increasingly expected to innovate in order to meet these demands in a safe manner. Pipeline development of biologics and personalised dermatology treatments with more sophisticated technologies to improve drug delivery formulations, safety and efficacy are anticipated to be the next paradigm shift in the dermatological drugs market.

In this report, we examine in detail the factors which are driving growth in the Dermatological Drugs Market, the key companies currently operating in the market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of dermatological drugs.
The Dermatological conditions examined in this report are: Psoriasis, Skin Infections, Acne and Dermatitis. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia and India.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Visiongain’s report also provides an analysis of the current leading players in the Dermatological Drugs Market. Historical financial performance is analysed, along with a breakdown of each company’s leading products and pipeline research, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“The colon targeting drug delivery market will grow with exponential growth of 14% over the forecast period from 2020-2030”, says Visiongain

The colon targeting drug delivery market has been used various polymers including biodegradable polymers, guar gum, pectin, chondroitin sulfate, dextran, chitosan, cyclodextrin, inulin, amylose, locust bean gum, and others

23 September 2019

Read

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!